Stocktoria
BIODESIX INC BDSX
BIODESIX INC (BDSX) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $88.5M at a -39.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.172 |
| Retained earnings / assets | -5.69 |
| EBIT / assets | -0.319 |
| Equity / liabilities | -0.027 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| BDSX | BIODESIX INC | 3/9 | -19.59 | — | +24.1% |
| BNR | Burning Rock Biotech Ltd | 5/9 | -11.46 | — | +9.2% |
| PSNL | Personalis, Inc. | 3/9 | 0.31 | — | -17.7% |
| XGN | EXAGEN INC. | 3/9 | -14.91 | — | +19.7% |
| CFOR | CapForce Inc. | 2/9 | -14.09 | 1 | — |
| GRAL | GRAIL, Inc. | 4/9 | -2.86 | — | +17.2% |
| BGLC | BioNexus Gene Lab Corp | 4/9 | 13.26 | — | — |
About BIODESIX INC
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. Further, it operates laboratories. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
FAQ
Is BDSX financially healthy?
BIODESIX INC's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does BDSX pay a dividend?
No, BIODESIX INC does not currently pay a dividend.
How profitable is BDSX?
In FY2025, BIODESIX INC had a net margin of -39.8%.
What is the analyst price target for BDSX?
The average Wall-Street price target for BIODESIX INC is $30.83, about 27.3% above the recent price, from 6 analysts (consensus: strong buy).
Is BDSX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on BIODESIX INC: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.